Five-Year Data Consolidate Cosentyx Benefits
Executive Summary
Cosentyx sales are growing at an impressive rate – up 37% in Q3 – and strong five-year safety and efficacy data in psoriatic arthritis and ankylosing spondylitis is likely to drive that growth even higher.
You may also be interested in...
Lilly's Taltz Approved For AS As New Guidelines Keep TNF Inhibitors In Front Line
VP Rebecca Morison said the ankylosing spondylitis indication adds more evidence of Taltz's benefits. She noted Lilly believes there should be fewer steps before AS patients access IL-17 inhibitors.
Lilly's Taltz Gets Closer To A Level Playing Field With Novartis' Cosentyx
Lilly reported positive results for Taltz in a second Phase III study in ankylosing spondylitis and plans to file for FDA approval this year, which would give the IL-17A inhibitor a label similar to its rival Cosentyx, for which Novartis is working hard to build, maintain and grow market share.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.